A study to understand the safety and effectiveness of a new drug called TAF for the treatment of long term hepatitis B infection in adolescents - Trial 2016-000785-37
Access comprehensive clinical trial information for 2016-000785-37 through Pure Global AI's free database. This phase not specified trial is sponsored by Gilead Sciences, Inc. and is currently status unknown. The study focuses on Chronic Hepatitis B.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2016-000785-37
Trial Details
EU Clinical Trials Register • 2016-000785-37
A study to understand the safety and effectiveness of a new drug called TAF for the treatment of long term hepatitis B infection in adolescents
Study Focus
Sponsor & Location
Gilead Sciences, Inc.
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
1) Pregnant females, females who are breastfeeding or who believe they may wish to become pregnant during the course of the study
ICD-10 Classifications
Acute hepatitis B
Chronic viral hepatitis B without delta-agent
Acute delta-(super)infection in chronic hepatitis B
Chronic viral hepatitis B without delta-agent : other and unspecified phase
Chronic viral hepatitis B without delta-agent : immune-tolerant phase
Data Source
EU Clinical Trials Register
2016-000785-37
Non-Device Trial